Dialysis world news

MediPoint: Renal Denervation Research Report- US Analysis, Trends, opportunity ... - Medgadget.com (blog) PDF Print

The report analyzes and presents an overview of MediPoint: Renal Denervation – US Analysis And Market Forecasts worldwide.

Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough of the past two years, and for good reason. Hypertension is one of the most prevalent chronic conditions worldwide, with some studies estimating that 50% of the adult population globally will have the disease in the next 20 years. With limited effectiveness from pharmacotherapy, medical device therapy has the potential for significant adoption in the treatment of resistive hypertension and uncontrolled hypertension, once efficacy and cost-effectiveness are proven. Additionally, the degree of blood pressure reduction found in long-term clinical trials from such a well-tolerated procedure has generated notable optimism about the intervention’s application in other conditions where hyperactivity of the sympathetic nervous system plays a significant role, such as congestive heart failure.

The renal denervation market in the United States will grow from essentially nothing in 2012 as the intervention was not approved for any indication in the United States in 2012. That is expected to change by the end of the forecast period in 2019. By then, the intervention is expected to be approved in both uncontrolled hypertension and resistant hypertension patients. The adoption of the procedure will be much higher in the US.

Browse Full Report With Full TOC: http://www.marketresearchreports.biz/analysis/179458


An overview of hypertension, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
Annualized US renal denervation market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
Investigation of current and future market competition for renal denervation
Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
Competitor assessment including device approval analysis and device sales forecasts.
Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
Analysis of unmet needs within the market and opportunities for future players.
Technology trends evaluation to assess strength of pipeline.
An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
Company profiles including business description, financial overview and SWOT analysis.
Coverage of key market players.
Strategic assessment of the renal denervation sector through market impact analysis, future market scenario and company analysis.
Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/179458

Reasons to buy

Understand the trends shaping and driving the US renal denervation market.
Realize device preferences of physicians who have performed the tests already.
Access market sizing, forecasts and quantified growth opportunities in the US renal denervation market through 2018.
Quantify candidate patient populations to better design product pricing & launch plans.
Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
Perform benchmarking analysis of growth opportunities against currently marketed products.
Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
What’s the next big thing in US renal denervation market landscape? Identify, understand and capitalize.

Browse All Reports of In Vitro Diagnostics: http://www.marketresearchreports.biz/category/61

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Top Related News: http://www.marketresearchreports.biz/articles

Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/


Wall Street Analysts Have $21 Price Target on NxStage Medical, Inc. (NASDAQ:NXTM) - Markets Daily PDF Print

There are 4 research firms in total that have issued ratings on NxStage Medical, Inc. (NASDAQ:NXTM) within the past year. The consensus, or mean target price of the Wall Street analysts covering the firm is $21.

Analysts are predicting that NxStage Medical, Inc. (NASDAQ:NXTM) will report $-0.1 earnings per share when they next issue their quarterly earnings release on or around 2015-08-06. The consensus mean estimate is the calculated mean of all brokerage sell-side analysts that issue earnings estimates for the company. In the most recent quarter the company reported earnings of $0 that ended on 2015-03-31. NxStage Medical, Inc. (NASDAQ:NXTM) has a 2 consensus analyst rating on the stock based on an arithmetical average of the 4 ratings given by the brokerage analysts covering the company. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell. The highest estimate of the 4 covering analysts sees the stock climbing to $24 within the next year while the lowest estimate places the 12-month target price at $15. Looking ahead to full year estimates, analysts have placed the consensus earnings per share estimate for the current year at $-0.35. The most bullish analyst sees the company reporting earnings per share of $-0.31 while the most bearish analyst is predicting a current year EPS number of $-0.42. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline ... - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/699tw6/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Insights" report to their offering.

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insights provides the in-depth analysis of the pipeline assets across the Acute Renal Failure (ARF) (Acute Kidney Injury) landscape. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Acute Renal Failure (ARF) (Acute Kidney Injury) Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insights Report covers the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline molecules at various stages of development like Pre-registration phases, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Acute Renal Failure (ARF) (Acute Kidney Injury) related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Acute Renal Failure (ARF) (Acute Kidney Injury).


- The report provides a Acute Renal Failure (ARF) (Acute Kidney Injury) Landscape across the globe.

- The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information.

- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type.

- The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and also provide company profiling.

- Pipeline products coverage based on various stages of development from NDA filings to discovery.

- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

For more information visit http://www.researchandmarkets.com/research/699tw6/acute_renal


Two dialysis centers open in Macon - Macon Telegraph PDF Print

Two dialysis centers open in Macon
Macon Telegraph
American Renal Associates LLC, in partnership with physicians of Central Georgia Kidney Specialists opened Macon Southside Dialysis Center at 2117 Eisenhower Parkway and the Dialysis Center of Macon at 890 Second St., according to a news release.


Revenue Update on DaVita HealthCare(NYSE:DVA) - Money Flow Index PDF Print

DaVita HealthCare(NYSE:DVA) announced the earnings results for Fiscal Year 2015 and Q2. The results came in during After-hours on Aug 4, 2015. Company reported revenue of $3.44B. The estimated revenue was of $3.37B. Earnings per share were $0.95. The reported EPS was above estimates by $0.01 or 1.06%. Analysts had estimated an EPS of $0.94.

DaVita healthCare Partners Inc. (NYSE:DVA) has dropped 0.45% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 0.11% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 1.6%. DaVita healthCare Partners Inc. (NYSE:DVA) has underperformed the index by 1.17% in the last 4 weeks. Investors should watch out for further signals and trade with caution. DaVita HealthCare Partners Inc. has dropped 4.09% during the last 3-month period . Year-to-Date the stock performance stands at 4.34%. The company shares have rallied 9.54% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $85.17 and one year low was seen on August 4, 2014 at $70.85. The 50-day moving average is $80.02 and the 200 day moving average is recorded at $79.7. S&P 500 has rallied 8.5% during the last 52-weeks. The company has received recommendation from many analysts. 5 analysts have rated the company as a strong buy. The shares have been rated as hold from 7 Wall Street Analysts. 1 analysts have suggested buy for the company. Underperform rating was given by 1 analyst. DaVita healthCare Partners Inc. (NYSE:DVA) : On Friday heightened volatility was witnessed in DaVita healthCare Partners Inc. (NYSE:DVA) which led to swings in the share price. The shares opened for trading at $78.63 and hit $79.61 on the upside , eventually ending the session at $79.03, with a gain of 0.51% or 0.4 points. The heightened volatility saw the trading volume jump to 671,630 shares. The 52-week high of the share price is $85.17 and the company has a market cap of $16,987 million. The 52-week low of the share price is at $70.49 . Currently the company Insiders own 0.2% of DaVita HealthCare Partners Inc. Company shares. In the past six months, there is a change of -53.07% in the total insider ownership. Institutional Investors own 86.5% of Company shares. During last 3 month period, -0.03% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Co-Chairman of the Board) of Davita Healthcare Partners Inc., Margolis Robert J had sold 31,400 shares worth of $2,619,074 in a transaction dated June 3, 2015. In this transaction, 31,400 shares were sold at $83.41 per share. DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysia’s Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd.


<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 25 of 2630
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.